与LABA相结合的ICS与Omalizumab在过敏喘患者的转录体表达特征上添加的Omalizumab的比较分析
Ya-Ru Liang1, Chuan-Hsin Chang2, Shiang-Yu Huang1
1Division of Respiratory Therapy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
Journal of asthma and allergy
|June 10, 2025
概括
严重喘的奥马利祖马布补充疗法通过降低免疫路径的调节显示出潜在的潜力,尽管一些患者保留了更高的IgE水平和呼吸道反应性. 进一步研究像cGMP-PKG信号传递这样的上调通路是有必要的.
科学领域:
- 分子生物学和免疫学 分子生物学和免疫学
- 呼吸系统药物 呼吸系统药物
- 药物基因组学 药物基因组学
背景情况:
- 喘是一种慢性呼吸道炎症,在全球显著影响生活质量.
- 吸入性皮质类固醇 (ICS) 与长效β-激动剂 (LABA) 是中度至重度喘的标准.
- 奥马利祖马布是ICS/LABA非响应患者的选择,但其转录基因效应尚未得到充分了解.
研究的目的:
- 为了研究喘患者的转录体表达特征.
- 为了比较ICS/LABA治疗和ICS/LABA加上奥马利祖马布之间的基因表达.
- 为了将转录组变化与严重喘管理中的临床结果相关联.
主要方法:
- 这是一项前性实验性研究,共有26名参与者 (10名ICS/LABA,12名ICS/LABA + omalizumab,4名对照).
- 收集的转录基因数据,IgE,过敏原敏感性,肺功能和喘控制测试 (ACT) 成绩.
- 利用生物信息学分析来解释基因表达模式.
主要成果:
- 接受奥马利祖马布治疗的患者表现出更高的IgE水平和动态肺功能变化.
- 基因表达分析揭示了免疫反应,NOD类受体,RIG-I,IL-17和抗氧化剂通路的下调.
- 上调基因与cGMP-PKG信号传递,心肌病和电压通路有关.
结论:
- 通过降低炎症通路的调节,奥马利祖马布补充疗法可能有利于严重的喘.
- 在奥马利祖马布 (omalizumab) 组中发现了持续的气道过敏反应和升高的IgE水平.
- 在cGMP-PKG,心肌病和通道途径的升调需要进一步的研究.
更多相关视频
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
10.3K
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
6.1K
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
241
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
241
01:17Drugs Used in Lower Respiratory Disorders: Overview
358
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
358